What is HC Wainwright’s Estimate for Insmed Q1 Earnings?

Insmed, Inc. (NASDAQ:INSM) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Insmed in a research report issued on Monday, February 23rd. HC Wainwright analyst A. Fein forecasts that the biopharmaceutical company will earn ($1.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $230.00 price target on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. HC Wainwright also issued estimates for Insmed’s Q2 2026 earnings at ($1.05) EPS, FY2028 earnings at $2.92 EPS and FY2029 earnings at $6.09 EPS.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.32) earnings per share.

A number of other brokerages have also weighed in on INSM. The Goldman Sachs Group upped their target price on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Barclays assumed coverage on Insmed in a report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 price objective for the company. Wells Fargo & Company lowered their target price on shares of Insmed from $234.00 to $208.00 and set an “overweight” rating on the stock in a research note on Friday. Morgan Stanley set a $166.00 target price on shares of Insmed in a research report on Friday. Finally, Rothschild & Co Redburn set a $263.00 price target on shares of Insmed in a report on Thursday, December 4th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $207.52.

Insmed Trading Down 0.3%

Shares of INSM stock opened at $158.62 on Tuesday. The company has a market capitalization of $34.19 billion, a PE ratio of -24.75 and a beta of 1.11. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The business’s fifty day moving average is $163.52 and its 200 day moving average is $164.58. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

Hedge Funds Weigh In On Insmed

A number of large investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the period. Kingsview Wealth Management LLC increased its position in Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 60 shares during the last quarter. Choreo LLC raised its stake in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Insmed by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares during the last quarter. Finally, ORG Partners LLC boosted its stake in shares of Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the period.

Insiders Place Their Bets

In other news, CEO William Lewis sold 19,215 shares of Insmed stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer owned 306,891 shares in the company, valued at approximately $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. This trade represents a 67.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 178,952 shares of company stock worth $30,222,170. 3.00% of the stock is owned by corporate insiders.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: UK MHRA granted marketing authorization for brensocatib (Brinsupri) in patients ≥12 with non‑CF bronchiectasis — expands EU/UK commercial opportunity and supports revenue upside. Insmed’s Brinsupri wins MHRA approval
• Positive Sentiment: Company reported Brinsupri sales that beat expectations and set a 2026 sales target, a near‑term commercial beat that can support multiple expansion and revenue revisions. Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target Set
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $230 price target — a bullish analyst stance that signals continued Wall Street conviction and a material upside vs. current levels. MarketBeat INSM coverage
• Neutral Sentiment: Mizuho trimmed its price target from $211 to $204 but maintained an “Outperform” rating — a small haircut to valuation assumptions but still an above‑market stance. Benzinga
• Neutral Sentiment: Investor letter coverage (Artisan Partners) highlighted that Insmed benefited from its lead product ARIKAYCE — supportive investor interest but not an immediate price driver. Insmed Gained from ARIKAYCE (Yahoo)
• Negative Sentiment: CEO William Lewis sold ~10,699 shares (multiple recent sales disclosed), a sizeable recurring insider sale that can sap sentiment even though management still holds a large stake. Insider trades alert
• Negative Sentiment: HC Wainwright cut its FY2028 and FY2029 EPS forecasts (and lowered some long‑range estimates), which could temper forward‑looking valuation models despite the buy rating. HC Wainwright estimates (MarketBeat)
• Negative Sentiment: Recent quarterly results showed an EPS miss and wide negative margins; while revenue grew strongly year‑over‑year, profitability and near‑term losses remain a concern for some investors. Earnings recap (MarketBeat)

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.